Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AF-130 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AF-130 capsule | EXPERIMENTAL | AF-130 oral capsules administered as a single dose or once daily for 7 days |
| AF-130 matching placebo capsule | PLACEBO_COMPARATOR | Oral placebo capsules to match AF-130 administered as a single dose or once daily for 7 days |
| Name | Type | Description |
|---|---|---|
| AF-130 | DRUG | AF-130 oral capsules (50 mg) administered as a single dose or once daily for 7 days |
| Placebo comparator | DRUG | AF-130 matching placebo capsule |
Inclusion Criteria: * Healthy males * Age 18 to 55 years * Body mass index of 18.0 to 35.0 kg/m2 * Willing and able to communicate and participate in the whole study * Must provide written informed consent * Must agree to use an adequate method of contraception Exclusion Criteria: * Participation...
AF-130 is an investigational small molecule developed by Merck & Company, Inc. (ticker MRK). It has been studied in a Phase 1 clinical trial in healthy male volunteers. Merck has not publicly disclosed the specific disease or condition AF-130 is intended to treat.
AF-130 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. Merck sponsored the Phase 1 pharmacokinetics study of AF-130 conducted in the United Kingdom.
AF-130 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The study was a randomized, double-blind, placebo-controlled pharmacokinetics trial in healthy subjects.
AF-130 has been evaluated in one completed Phase 1 trial, NCT02652936, titled A Pharmacokinetics Study of AF-130 in Healthy Subjects. The trial enrolled 80 healthy male volunteers aged 18 years and older in the United Kingdom and was randomized, double-blind, and placebo-controlled.
AF-130 is not approved. It is an investigational small molecule that has completed a single Phase 1 pharmacokinetics study in healthy volunteers. No Phase 2 or later-stage trials of AF-130 are listed, and its development status beyond Phase 1 has not been announced.